Shareholder deadlines set for TuHURA (NASDAQ: HURA) 2026 meeting

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. has scheduled its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. This date is more than 30 days after the prior 2025 Special Meeting held on June 23, 2025, which resets shareholder proposal and nomination deadlines.

Stockholder proposals for inclusion in the proxy materials under Rule 14a-8, as well as proxy access director nominations, other proposals, and director nominations under the Bylaws and Rule 14a-19, must be received at the company’s Tampa, Florida principal executive offices by June 27, 2026.

8-K Event Classification

Item 5.08 — Shareholder Director Nominations

1 item

Item 5.08 Shareholder Director Nominations Governance

Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.

Key Figures

2026 Annual Meeting date: August 18, 2026 Rule 14a-8 proposal deadline: June 27, 2026 Proxy access nomination deadline: June 27, 2026 +2 more

5 metrics

2026 Annual Meeting date August 18, 2026 Virtual 2026 Annual Meeting of Stockholders

Rule 14a-8 proposal deadline June 27, 2026 Cutoff for inclusion in 2026 proxy statement

Proxy access nomination deadline June 27, 2026 Deadline for proxy access director nominations

Universal proxy notice deadline June 27, 2026 Rule 14a-19 solicitation notice for 2026 meeting

Prior special meeting date June 23, 2025 2025 Special Meeting in lieu of annual meeting

Key Terms

Rule 14a-8, proxy access, Rule 14a-19, universal proxy rule, +1 more

5 terms

Rule 14a-8 regulatory

"In order for a stockholder proposal, submitted solely pursuant to Rule 14a-8 of the Exchange Act, to be considered timely..."

Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.

proxy access regulatory

"The Company’s Bylaws provide stockholders with a proxy access right that permits a stockholder to nominate and include..."

Proxy access allows shareholders to include their nominated directors on a company’s official proxy ballot and meeting materials, instead of running separate, costly campaigns. It matters to investors because it makes it easier for shareholders to push for board change, hold management accountable, and influence strategy—similar to getting your preferred candidate listed on a neighborhood ballot rather than having to start an independent petition drive.

Rule 14a-19 regulatory

"stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees... in accordance with Rule 14a-19 of the Exchange Act"

Rule 14a-19 is a U.S. Securities and Exchange Commission rule that governs how independent proxy advisory firms produce and distribute voting recommendations for shareholders. It requires these advisers to provide companies with notice of their recommendations and a chance to respond, and to disclose certain conflicts; think of it as a referee ensuring both sides see a game plan before fans cast votes. Investors care because proxy advisers influence voting outcomes and corporate governance, so the rule affects transparency, potential bias, and the reliability of guidance that many investors rely on when voting shares.

universal proxy rule regulatory

"in accordance with Rule 14a-19 of the Exchange Act, also known as the universal proxy rule"

Amended and Restated Bylaws regulatory

"the deadlines set forth in the Company’s Amended and Restated Bylaws (the “Bylaws”) for stockholders to submit a notice..."

A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/17/2026 - 04:30 PM Accepted by SEC EDGAR 06/17/2026 - 04:30 PM

FAQ

When will TuHURA Biosciences (HURA) hold its 2026 Annual Meeting?

TuHURA Biosciences will hold its 2026 Annual Meeting of Stockholders virtually on August 18, 2026. The company will provide further details in a Definitive Proxy Statement on Schedule 14A to be filed with the SEC before the meeting.

What is the deadline for TuHURA (HURA) shareholder proposals under Rule 14a-8 for 2026?

Shareholder proposals seeking inclusion in TuHURA’s 2026 proxy materials under Rule 14a-8 must be received by June 27, 2026. Proposals must also meet all Rule 14a-8 requirements, including subject-matter and documentation conditions, and be delivered to the company’s Tampa, Florida executive offices.

How can TuHURA (HURA) shareholders use proxy access for director nominations in 2026?

TuHURA’s Bylaws provide proxy access for qualifying shareholders to include director nominees in company proxy materials. A proxy access notice of nominations must be received by June 27, 2026 at the Tampa address and comply with all Bylaw requirements on form, content, and eligibility.

What is the deadline for TuHURA (HURA) shareholder proposals outside Rule 14a-8 for the 2026 meeting?

For proposals or director nominations outside Rule 14a-8, TuHURA shareholders must deliver notice under the Bylaws by the close of business on June 27, 2026. The notice must satisfy all Bylaw content requirements for it to be considered at the 2026 Annual Meeting.

What must TuHURA (HURA) shareholders do under Rule 14a-19’s universal proxy rule for 2026?

Shareholders intending to solicit proxies in support of their own director nominees at TuHURA’s 2026 meeting must notify the Corporate Secretary by June 27, 2026. The notice must satisfy Rule 14a-19 and Bylaw requirements, including specified information about the nominees and solicitation plans.

Does postponing TuHURA’s 2026 Annual Meeting change shareholder proposal deadlines?

The company states that adjourning or postponing the 2026 Annual Meeting, or announcing such a change, will not start a new deadline period. Existing cutoff dates, including June 27, 2026 for proposals and nominations, remain in effect despite any adjournment or postponement.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 17, 2026

    

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)


Nevada	001-37823	99-0360497
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

10500 University Center Dr., Suite 110
Tampa, Florida 33612
(Address of Principal Executive Offices, including zip code)
Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     
Title of each class

     Trading
Symbol(s)

Name of each exchange on which registered

     Common Stock, $0.001 par value per share
 
     HURA

     The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.08 Shareholder Director Nominations.

The board of directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) has determined that the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) will be held virtually on August 18, 2026. More detailed information regarding the 2026 Annual Meeting will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A to be filed with the Securities and Exchange Commission (“SEC”). Because the date of the 2026 Annual Meeting has been changed by more than 30 days from the anniversary date of the Company’s 2025 Special Meeting in Lieu of an Annual Meeting of the Stockholders held on June 23, 2025 (the “2025 Special Meeting”), in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is hereby informing stockholders of such change. In addition, because the 2026 Annual Meeting will be held more than 30 days from the anniversary date of the 2025 Special Meeting, the deadlines for the submission of stockholder proposals pursuant to Rule 14a-8 of the Exchange Act and director nominations pursuant to the Company’s proxy access rights, in each case for consideration at the 2026 Annual Meeting, no longer apply. Further, because the 2026 Annual Meeting will be held more than 25 days from the anniversary date of the 2025 Special Meeting, the deadlines set forth in the Company’s Amended and Restated Bylaws (the “Bylaws”) for stockholders to submit a notice of a proposal outside the processes of Rule 14a-8 of the Exchange Act and a notice of proposed director nominations, in each case for consideration at the 2026 Annual Meeting, no longer apply.

In order for a stockholder proposal, submitted solely pursuant to Rule 14a-8 of the Exchange Act, to be considered timely for inclusion in the Company’s proxy statement and form of proxy for the 2026 Annual Meeting, such proposal must be received by the Company by June 27, 2026. Therefore, in order for a stockholder to submit a proposal for inclusion in the Company’s proxy materials for the 2026 Annual Meeting, the stockholder must comply with the requirements set forth in Rule 14a-8, including, without limitation, with respect to the subject matter of the proposal, and must deliver the proposal and all required documentation to the Company at its principal executive offices at the address set forth below no later than June 27, 2026. The public announcement of an adjournment or postponement of the date of the 2026 Annual Meeting will not commence a new time period (or extend any time period) for submitting a proposal pursuant to Rule 14a-8. Any such stockholder proposals should be mailed to the Company at the following address: TuHURA Biosciences, Inc., 10500 University Center Dr., Suite 110, Tampa, Florida 33612, Attn.: Secretary.

The Company’s Bylaws provide stockholders with a proxy access right that permits a stockholder to nominate and include in the Company’s proxy materials director nominees, provided that the stockholder and the nominee(s) satisfy the requirements specified in the Bylaws. A stockholder who intends to nominate and include in the Company’s proxy materials proxy access director nominees must cause a notice of nominations of such proxy access nominees to be received by the Company at the same address provided above no later than the close of business on June 27, 2026, which is the 10th day following the first public disclosure by the Company of the date of the 2026 Annual Meeting, and must comply with the other requirements of the Bylaws, including, but not limited to, the requirements with respect to the form and content of a proxy access notice of nominations. Any notice of proxy access nominations received after such date will be considered untimely. In no event shall any adjournment or postponement of the 2026 Annual Meeting, or the announcement thereof, commence a new time period for the giving of such notice of proxy access nominations.

Because the 2026 Annual Meeting will be held more than 25 days from the anniversary date of the 2025 Special Meeting, to be timely in accordance with the Bylaws, stockholders intending to submit a proposal outside the processes of Rule 14a-8 of the Exchange Act or a proposed director nomination, in each case for consideration at the 2026 Annual Meeting, must cause a notice of such proposal and/or proposed director nomination to be received by the Company at the same address provided above no later than the close of business on June 27, 2026, which is the 10th day following the first public disclosure by the Company of the date of the 2026 Annual Meeting. In addition to satisfying the requirements under the Bylaws, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees at the 2026 Annual Meeting must provide notice to the Company’s Corporate Secretary no later than June 27, 2026 in accordance with Rule 14a-19 of the Exchange Act, also known as the universal proxy rule. In no event shall any adjournment or postponement of the 2026 Annual Meeting, or the announcement thereof, commence a new time period for the giving of such notices. Such notices must also comply with all other requirements set forth in the Bylaws (which, in the case of proposed director nominations, also requires the information required by Rule 14a-19 of the Exchange Act), the Exchange Act, and other applicable laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			TUHURA BIOSCIENCES, INC.

Date:	June 17, 2026	By:	/s/ Dan Dearborn
			Name: Dan Dearborn Title: Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document